Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis

Statin use in end-stage kidney disease (ESKD) patients are not encouraged due to low cardioprotective effects. Although the risk of hepatocellular carcinoma (HCC), a frequently occurring cancer in East Asia, is elevated in ESKD patients, the relationship between statins and HCC is not known despite...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2022-06, Vol.12 (1), p.10807-10807, Article 10807
Main Authors: Kim, Hyung Woo, Joo, Young Su, Kang, Shin Chan, Koh, Hee Byung, Han, Seung Hyeok, Yoo, Tae-Hyun, Kang, Shin-Wook, Park, Jung Tak
Format: Article
Language:English
Subjects:
692/4020
692/4022
Chronic infection
Dialysis
End-stage renal disease
Hemodialysis
Hepatitis
Hepatitis B
Hepatocellular carcinoma
Humanities and Social Sciences
Kidney diseases
Kidneys
Liver cancer
multidisciplinary
Patients
Science
Science (multidisciplinary)
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Statin use in end-stage kidney disease (ESKD) patients are not encouraged due to low cardioprotective effects. Although the risk of hepatocellular carcinoma (HCC), a frequently occurring cancer in East Asia, is elevated in ESKD patients, the relationship between statins and HCC is not known despite its possible chemopreventive effect. The relationship between statin use and HCC development in ESKD patients with chronic hepatitis was evaluated. In total, 6165 dialysis patients with chronic hepatitis B or C were selected from a national health insurance database. Patients prescribed with ≥ 28 cumulative defined daily doses of statins during the first 3 months after dialysis commencement were defined as statin users, while those not prescribed with statins were considered as non-users. Primary outcome was the first diagnosis of HCC. Sub-distribution hazard model with inverse probability of treatment weighting was used to estimate HCC risk considering death as competing risk. During a median follow-up of 2.8 years, HCC occurred in 114 (3.2%) statin non-users and 33 (1.2%) statin users. The HCC risk was 41% lower in statin users than in non-users (sub-distribution hazard ratio, 0.59; 95% confidence interval [CI], 0.42–0.81). The weighted incidence rate of HCC was lower in statin users than in statin non-users (incidence rate difference, − 3.7; 95% CI − 5.7 to − 1.7; P  
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-14713-w